Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study - PubMed
5 hours ago
- #KCCQ
- #ATTR-CM
- #Vutrisiran
- Vutrisiran improved overall health status in ATTR-CM patients in the HELIOS-B study.
- Analysis focused on 23 KCCQ components, showing favorable changes with vutrisiran compared to placebo.
- Greatest benefits were seen in physical limitations like hurrying/jogging and walking, and quality-of-life aspects.
- Benefits were similar or greater in patients not taking tafamidis at baseline.
- Vutrisiran shifted the age-KCCQ-OSS relationship by about 11 years, indicating improved health status relative to age.